These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10732759)

  • 1. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
    Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
    BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of bone turnover in prostate cancer.
    Garnero P
    Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
    Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
    Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases.
    Zafeirakis AG; Papatheodorou GA; Limouris GS
    Nucl Med Commun; 2010 Mar; 31(3):249-53. PubMed ID: 20038858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
    Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
    Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
    Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
    Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
    Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.